Molecular mechanisms in MASLD/MASH related HCC

Xiaobo Wang,Liang Zhang,Bingning Dong
DOI: https://doi.org/10.1097/hep.0000000000000786
IF: 17.298
2024-02-13
Hepatology
Abstract:Liver cancer is the third leading cause of cancer-related deaths and ranks as the sixth most prevalent cancer type globally. Nonalcoholic fatty liver disease (NAFLD) or metabolic dysfunction-associated steatotic liver disease (MASLD), and its more severe manifestation, nonalcoholic steatohepatitis (NASH) or metabolic dysfunction-associated steatohepatitis (MASH), pose a significant global health concern, affecting approximately 20–25% of the population. The increased prevalence of MASLD and MASH is parallel to the increasing rates of obesity-associated metabolic diseases, including type 2 diabetes, insulin resistance, and fatty liver diseases. MASH can progress to MASH-related hepatocellular carcinoma (MASH-HCC) in about 2% of cases each year, influenced by various factors such as genetic mutations, carcinogen exposure, immune microenvironment, and microbiome. MASH-HCC exhibits distinct molecular and immune characteristics compared to other causes of HCC and affects both men and women equally. The management of early to intermediate stage MASH-HCC typically involves surgery and locoregional therapies, while advanced HCC is treated with systemic therapies, including anti-angiogenic therapies and immune checkpoint inhibitors. In this comprehensive review, we consolidate previous research findings while also providing the most current insights into the intricate molecular processes underlying MASH-HCC development. We delve into MASH-HCC associated genetic variations and somatic mutations, disease progression and research models, multi-omics analysis, immunological and microenvironmental impacts, and discuss targeted/combined therapies to overcome immune evasion and the biomarkers to recognize treatment responders. By furthering our comprehension of the molecular mechanisms underlying MASH-HCC, our goal is to catalyze the advancement of more potent treatment strategies, ultimately leading to enhanced patient outcomes.
gastroenterology & hepatology
What problem does this paper attempt to address?